Organogenesis Holdings Inc. (ORGO)
NASDAQ: ORGO · IEX Real-Time Price · USD
2.760
+0.140 (5.34%)
Mar 27, 2024, 4:00 PM EDT - Market closed

Organogenesis Holdings Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019201820172016
Net Income
4.9515.5394.217.23-39.28-64.83-8.81-16.99
Depreciation & Amortization
23.4518.0316.688.189.836.985.637.32
Share-Based Compensation
96.553.861.660.941.080.920.47
Other Operating Activities
-6.47-15.26-52.76-21.61-5.58-3.86-1.654.32
Operating Cash Flow
30.9224.8661.985.47-33.53-60.64-3.49-4.87
Operating Cash Flow Growth
24.37%-59.89%1033.88%-----
Capital Expenditures
-24.36-33.9-31.22-17.68-6.23-1.86-2.42-1.25
Acquisitions
000-5.8200-14.960
Other Investing Activities
------2.5-
Investing Cash Flow
-24.36-33.9-31.22-23.5-6.23-1.86-14.87-1.25
Share Issuance / Repurchase
02.072.261.941.591.850.220
Debt Issued / Paid
-5.17-3.01-2.01-15.9137.230.920.1511.95
Other Financing Activities
-0.33-1.26-1.22-3.52--11.21-1.5-5.18
Financing Cash Flow
-5.51-2.2-1.0442.4778.7381.5418.876.78
Net Cash Flow
1.05-11.2429.7224.4438.9719.050.50.66
Free Cash Flow
6.55-9.0430.76-12.21-39.76-62.49-5.91-6.12
Free Cash Flow Margin
1.51%-2.00%6.58%-3.61%-15.24%-32.30%-2.98%-4.41%
Free Cash Flow Per Share
0.05-0.070.24-0.11-0.43-0.90-0.09-0.10
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).